London Biotechnology Show’s Post

Learn about the importance of organoids in drug development in a fascinating article featuring Charles River’s @Dan Rocca and @Louise Brackenbury by @Genetic Engineering & Biotechnology News. Read the article in full: https://bit.ly/3vMwsyW

#organoids are transforming our abilities to make assays and models more relevant to human disease. Read about #organoids in this fascinating article.

Learn about the importance of #organoids in drug development in a fascinating article featuring @Dan Rocca and @Louise Brackenbury by @Genetic Engineering & Biotechnology News. Read the article in full: https://bit.ly/3vMwsyW

Blood cancer continues to be a devastating disease, requiring ongoing research and support to advance treatments and improve access to care. Philanthropy plays a key role in driving innovation and expanding access, especially for underserved communities. In a recent interview with us, Lore Gruenbaum, VP of Research for The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP), discussed how philanthropic efforts can bridge the gap between research and clinical application. She highlighted promising areas for future investment, strategies to improve treatment access, and the potential of innovations like gene editing and immunotherapy to transform care. Read more here https://lnkd.in/gPzynyKi #lbs #lbs25 #londonbiotechnologyshow #biotechnology #bioinformatics #medtech #innovation #lifesciences #healthcare #pharmaceutical #biomedicalengineering #tissueengineering #biotechconference #biotechevent #biotechexpo #redbiotechnology #excellondon #londonbiotech

I am thrilled to share that our paper, "A Comparison of Branched DNA and Reverse Transcriptase Quantitative Polymerase Chain Reaction Methodologies for Quantitation of Lipid Nanoparticle Encapsulated mRNA", has been published in the Bioanalysis Journal! This work represents a significant step forward in mRNA quantification, particularly highlighting the transition from bDNA to RT-qPCR methodologies for encapsulated mRNA. Our study provides insights that could serve as a blueprint for regulatory agencies and biotechnology companies working on mRNA-based therapeutics. Special thanks to my amazing co-authors and collaborators for their hard work and dedication. #science #biotechnology #research #mRNA #bioanalysis #PCR #pharmacokinetics #publication Read the full paper here: https://lnkd.in/gtXBQmp3

𝐂𝐞𝐥𝐥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐌𝐞𝐝𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐄𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 $𝟏𝟑.𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/dNMpEu8m The global cell culture media market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $13.0 billion by 2028, growing at a CAGR of 16.0% from 2023 to 2028. Recent Developments of Cell Culture Media Industry: - In June 2023, Thermo fisher launched Tumoroid Culture Medium to accelerate development of novel cancer therapies. - In April 2023, FUJIFILM Irvine Scientific launched BalanCD CHO Media Platform Portfolio for Bioprocessing. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Thermo Fisher Scientific Merck Life Science Danaher Corporation Sartorius Corning Incorporated FUJIFILM Holdings Corporation Lonza Becton, Dickinson and Company STEMCELL Technologies STEMCELL Technologies China Miltenyi Biotec HiMedia Laboratories Pvt. Ltd. BIOLOGOS Cell Applications, Inc. Caisson Laboratories PromoCell Cell Biologics, Inc InvivoGen PAN-Biotech GmbH Cellular Technology Limited — CTL ZenBio Athena Enzyme Systems Cyagen BIOSCIENCES Cyagen Korea Biowest Akron BioTECH KCell Biosciences Welgene Inc. faCellitate Biological Industries Sartorius Nucleus Biologics Bitesize Bio Superworth Biodiscoveries Pvt. Ltd. SIGNICENT PELOBiotech GmbH ATCC #cellculturemedia #cellculturemediamarket #cellculturemediamarketsize #cellculturemediacompanies #biotech #biotechnology

Antibody cloning is a fundamental technique in molecular biology and biotechnology, essential for the production of monoclonal antibodies. These antibodies are invaluable tools in research, diagnostics, and therapeutics. Advantages of Antibody Cloning Specificity: Cloned antibodies are highly specific to the target antigen. Reproducibility: They provide consistent results across different experiments. Scalability: Large quantities can be produced for various applications. https://lnkd.in/gNByRpVQ #AntibodyCloning #MolecularBiology #Biotechnology #MonoclonalAntibodies #ResearchTools #Diagnostics #Therapeutics #Specificity #Reproducibility #Scalability #CustomAntibodies #KMDBIOSCIENCE

🧬🔬💡Discover the groundbreaking work on mRNA-based engineering of immune cells! 👩🔬Professor Chantal Pichon, Head of the ART ARNm Research Unit at the French Institute of Health and Medical Research (Inserm) 📅 February 27th | 14h (UTC time) 👉 Zoom: https://lnkd.in/dgcc6-uE As part of the ongoing webinar series on Unlocking mRNA's potential for therapeutic innovations, we are thrilled to receive Professor Pichon's lab, Innovative Therapies & Nanomedicine, focuses on the use of nucleic acids, especially messenger RNAs, as vaccines and therapeutics. Additionally, her lab is also developing a challenging project to build an economically sustainable biotechnology process for production of high-quality mRNA therapeutics, opening their use for different applications. 📣Join us to know all about it! #witheyesetonthefuture #followbluepharma #Bluepharma #Bluepharma22anos #Bluepharmaacelera2030 #pharmaceuticalindustry #pharmaceutical #industry #indústriafarmacêutica #innovation #development #technology #health #pharmaceuticals #Pharma #lifescience #future #event #science #Portugal #Cintech #PRR #UC #CNC #UCoimbra #mRNA #Therapeutics #InnovativeTherapies #research Universidade de Coimbra Center for Neuroscience and Cell Biology

We saw how programs with great value suffered hopelessly trying to manufacture enough iPSC-derived therapeutic cells for later trial needs. Start with good iPSCs reprogrammed to completion, or re-reprogram the iPSCs you have deeply vested with the Allele's mRNA method so that the iPSCs can passage well into the billions without any spontaneous differentiation or crashing. #iPSC, #GMP_iPSC, #CIRM, #Cell_Therapy_CDMO

𝐂𝐑𝐈𝐒𝐏𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐭𝐨 𝐆𝐫𝐨𝐰 $7.1 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭https://lnkd.in/gaxGHcen The global CRISPR market in terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028. 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 Tango Therapeutics Jumpcode Genomics Metagenomi Capsida Biotherapeutics Scribe Therapeutics BRAIN Biotech AG ZeClinics Gameto Fios Genomics Mustang Bio genOway Addgene BPS Bioscience Inc. Apprentice.io Hudson River Biotechnology Enceladus Bio TwinStrand Biosciences Lykan Bioscience - Now RoslinCT Myllia Biotechnology ASC Therapeutics Avectas TransCode Therapeutics, Inc. Tavros Therapeutics Cytosurge Applied Biological Materials Umeå University Friedrich-Loeffler-Institut Modalis Therapeutics Samplix Artisan Bio SeQure Dx Colossal Biosciences Synbio Technologies Repare Therapeutics Transnetyx Robigo Medical Technologies Innovation Facility RoslinCT Donnelly Centre for Cellular and Biomolecular Research, University of Toronto DefiniGEN